Further, blocking HDAC6 activity directly with tubacin or indirectly by blocking its post-translational modifier NEDD8 with MLN4924, provides options for new therapeutic strategies to treat or reverse endothelial dysfunction and atherosclerosis. The gene discussed is HDAC6; the disease is endothelial dysfunction.